tetano
Editor, Senior Moderator
CEN Case Rep
. 2020 Sep 4.
doi: 10.1007/s13730-020-00524-3. Online ahead of print.
COVİD-19 infection in a membranous nephropathy patient treated with rituximab
Omer Celal Elcioglu[SUP] 1 [/SUP], Ayse Serra Artan[SUP] 2 [/SUP], Safak Mirioglu[SUP] 2 [/SUP], Meltem Gursu[SUP] 2 [/SUP], Bulent Durdu[SUP] 3 [/SUP], Meliha Meric Koc[SUP] 3 [/SUP], Fatmanur Okyaltirik[SUP] 4 [/SUP], Mehmet Ali Gultekin[SUP] 5 [/SUP], Rumeyza Kazancioglu[SUP] 2 [/SUP]
Affiliations
Abstract
While COVID-19 pandemic continues to affect our country and most countries in the world, we have to make some changes both in our social life and our approach to healthcare. We have to struggle with the pandemic on one hand and also try to follow up and treat our patients with chronic diseases in the most appropriate way. In this period, one of our group of patients who are challenging us for follow-up and treatment are those who should start or continue to use immunosuppressive therapy. In order to contribute to the accumulation of knowledge in this area, we wanted to report a patient who was followed up with the diagnosis of COVID-19 and had been administered rituximab very recently due to a nephrotic syndrome caused by membranous nephropathy.
Keywords: COVID-19; Coronavirus; Immunosuppression; Membranous nephropathy; Rituximab.
. 2020 Sep 4.
doi: 10.1007/s13730-020-00524-3. Online ahead of print.
COVİD-19 infection in a membranous nephropathy patient treated with rituximab
Omer Celal Elcioglu[SUP] 1 [/SUP], Ayse Serra Artan[SUP] 2 [/SUP], Safak Mirioglu[SUP] 2 [/SUP], Meltem Gursu[SUP] 2 [/SUP], Bulent Durdu[SUP] 3 [/SUP], Meliha Meric Koc[SUP] 3 [/SUP], Fatmanur Okyaltirik[SUP] 4 [/SUP], Mehmet Ali Gultekin[SUP] 5 [/SUP], Rumeyza Kazancioglu[SUP] 2 [/SUP]
Affiliations
- PMID: 32888168
- DOI: 10.1007/s13730-020-00524-3
Abstract
While COVID-19 pandemic continues to affect our country and most countries in the world, we have to make some changes both in our social life and our approach to healthcare. We have to struggle with the pandemic on one hand and also try to follow up and treat our patients with chronic diseases in the most appropriate way. In this period, one of our group of patients who are challenging us for follow-up and treatment are those who should start or continue to use immunosuppressive therapy. In order to contribute to the accumulation of knowledge in this area, we wanted to report a patient who was followed up with the diagnosis of COVID-19 and had been administered rituximab very recently due to a nephrotic syndrome caused by membranous nephropathy.
Keywords: COVID-19; Coronavirus; Immunosuppression; Membranous nephropathy; Rituximab.